Image source: NewLink Genetics.
What: After NewLink Genetics Corporation (NASDAQ: NLNK) reported that its pancreatic cancer treatment algenpantucel-L failed to outperform standard of care, its shares lost a third of their value at 12:00 p.m. ET today.